BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC
The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer
Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.
Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL
The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.
